Irbesartan Generics [uk]

Irbesartan, the active ingredient in Irbesartan Generics, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to manage high blood pressure and to help slow the progression of kidney disease in patients with diabetes. By selectively blocking the AT1 receptor, it reduces vasoconstriction and aldosterone‑mediated fluid retention, supporting cardiovascular health in adult patients.

GNH USA supplies Irbesartan Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker used to treat conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure, reducing risk of cardiovascular complications. - Diabetic nephropathy: slows the progression of renal disease in patients with type 2 diabetes and proteinuria.

Irbesartan may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach with urge to vomit. - Abdominal pain: discomfort in the stomach area. - Elevated serum potassium: mild increase in blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Acute renal impairment: sudden decline in kidney function. - Hepatic injury: signs of liver damage such as jaundice. - Neutropenia: significant reduction in white blood cells. - Anaphylaxis: life‑threatening allergic reaction with rash, difficulty breathing, and circulatory collapse.

When prescribing Irbesartan, clinicians should consider several safety measures. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Renal function assessment: check serum creatinine and eGFR before and during therapy. - Serum potassium evaluation: monitor for hyperkalaemia, especially with concomitant potassium‑sparing agents. - Pregnancy caution: avoid use in pregnancy due to fetal risk (Category D). - Hepatic impairment: use with caution in patients with severe liver disease. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase renal risk. - Dual ARB/ACE‑inhibitor therapy: heightened risk of hypotension, hyperkalaemia, and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous elevations in serum potassium.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive effect and impair renal function. - Strong CYP2C9 inhibitors (e.g., fluconazole): may increase Irbesartan plasma concentrations.